Literature

• AmNA™

  Yahara A, Shrestha AR, Yamamoto T, Hari Y, Osawa T, Yamaguchi M, Nishida M, Kodama T, Obika S.
  Amido-Bridged Nucleic Acids (AmNAs): Synthesis, Duplex Stability, Nuclease Resistance, and in Vitro Antisense Potency, ChemBioChem, 2012, 13, 2513 – 2516

  Yamamoto T, Yahara A, Waki R, Yasuhara H, Wada F, Harada-Shiba M, Obika S.
  Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense oligonucleotides in vivo, Org Biomol Chem. 2015,13,12, 3757-65

  Setoguchi K, Cui L, Hachisuka N, Obchoei S, Shinkai K, Hyodo F, Kato K, Wada F, Yamamoto T, Harada-Shiba M, Obika S, Nakano K.
  Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes, Molecular Therapy: Nucleic Acids, 2017, 9, 170-181

  Shimojo M, Kasahara Y, Inoue M, Tsunoda S, Shudo Y, Kurata T, Obika S.
  A Gapmer Antisense Oligonucleotide Targeting SRRM4 Is a Novel Therapeutic Medicine for Lung. Cancer, Sci. Rep. 2019, 9,1

  Uehara T, Choong CJ, Nakamori M, Hayakawa H, Nishiyama K, Kasahara Y, Baba K, Nagata T, Yokota T, Tsuda H, Obika S, Mochizuki H.
  Amido-bridged Nucleic Acid (AmNA)-modified Antisense Oligonucleotides Targeting -synuclein As A Novel Therapy For Parkinson’s disease, Scientific Reports, 2019, 9:7567

  Kanda M, Kasahara Y, Shimizu D, Miwa T, Umeda S, Sawaki K, Nakamura S, Kodera Y, Obika S.
  Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting SYT13 to Treat Peritoneal Metastasis of Gastric Cancer, Molecular Therapy: Nucleic Acids, 2020, 22, 791-802

  Wada F, Yamamoto T, Kobayashi T, Tachibana K, Ito KR, Hamasaki M, Kayaba Y, Terada C, Yamayoshi A, Obika S, Harada-Shiba M.
  Drug Discovery and Development Scheme For Liver-targeting Bridged Nucleic Acid Antisense Oligonucleotides, Molecular Therapy: Nucleic Acids, 2021, 26, 957~969

  Shimo T, Nakatsuji Y, Tachibana K, Obika S.
  Design and In Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids, Int. J. Mol. Sci. 2021, 22, 3526.

  Yoshida M, Oda C, Mishima K, Tsuji I, Obika S, Shimojo M.
  An Antisense Amido-bridged Nucleic Acid Gapmer Oligonucleotide Targeting SRRM4 Alters REST Splicing And Exhibits Anti-tumor Effects in Small Cell Lung Cancer And Prostate Cancer Cells, Cancer Cell Int, 2023, 23, 8

  Kanda M, Takano N, Miyauchi H, Ueda K, Mizuno M, Kasahara Y, Kodera Y, Obika S.
  Preclinical Toxicological Assessment of Amido‑bridged Nucleic Acid‑modified Antisense Oligonucleotides Targeting Synaptotagmin XIII For Intra‑abdominal Treatment Of Peritoneal Metastasis Of Gastric Cancer, Gastric Cancer , 2024, 27,1229–1241

  Kuroda M, Kasahara Y, Hirose M, Yamaguma H, Oda M, Nagao C, Mizuguchi K.
  Construction of a Tm-value prediction model and molecular dynamics study of AmNA-containing gapmer antisense oligonucleotide, Molecular Therapy: Nucleic Acids, 2024, 35, 3, 102272

  Uchibori Y, Suekuni M, Kokaji Y, Yoshida K, Kiyono T, Kasahara Y, Fujita M.
  AmNA-Modified Antisense Oligonucleotide Targeting MCM8 as a Cancer-Specific Chemosensitizer for Platinum Compounds, Cancer Science, 2025; 116, 1405–1416

  Kawanobe T, Asano S, Kandori H, Aoki M, Shrestha AR, Sekiguchi K, Yokoyama K, Fukuda R, Umemoto T.
  Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid, Nucleic Acid Ther, 2025, 35, 3, 114-124

  Sowa N, Horie T, Ide Y, Baba O, Kora K, Yoshida T, Nakamura Y, Matsumoto S, Matsushita K, Imanaka M, Zou F, Kume E, Kojima H, Qian Q, Kimura K, Otsuka R, Hara N, Yamasaki T, Otani C, Tsujisawa Y, Takaya T, Nishimura C, Watanabe D, Hasegawa K, Kotera J, Oka K, Fujita R, Takemiya A, Sasaki T, Kasahara Y, Obika S, Kimura T, Ono K.
  MicroRNA-33 inhibition ameliorates muscular dystrophy by enhancing skeletal muscle regeneration, EMBO Molecular Medicine, 2025, 17, 1902-1925

• scpBNA™

  https://www.glenresearch.com/reports/gr36-21

  Yamaguchi T, Horiba M, Obika S.
  Synthesis and Properties of 2’-O,4’-C-spirocyclopropylene Bridged Nucleic Acid (scpBNA), an Analogue of 2’,4’- BNA/LNA Bearing a Cyclopropane Ring, Chem. Commun., 2015, 51, 9737

  Horiba M, Yamaguchi T, Obika S.
  Synthesis of scpBNA-mC, -A, and -G Monomers and Evaluation of the Binding Affinities of scpBNA-Modified Oligonucleotides toward Complementary ssRNA and ssDNA, J. Org. Chem. 2016, 81, 22, 11000-11008.

  Kawanobe T, Asano S, Kandori H, Aoki M, Shrestha AR, Sekiguchi K, Yokoyama K, Fukuda R, Umemoto T.
  Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid, Nucleic Acid Ther, 2025, 35, 3, 114-124

• Dual Modification (Base Modification of scpBNA)

  Habuchi T, Yamaguchi T, Aoyama H, Horiba M, Ito KR, Obika S.
  Hybridization and Mismatch Discrimination Abilities of 2′,4′-Bridged Nucleic Acids Bearing 2‑Thiothymine or 2‑Selenothymine Nucleobase, J. Org. Chem. 2019, 84, 1430-1439.

  Sakurai Y, Yamaguchi T, Yoshida T, Horiba M, Inoue T, Obika S.
  Synthesis and Properties of Nucleobase-Sugar Dual Modified Nucleic Acids: 2′‑OMe-RNA and scpBNA Bearing a 5‑Hydroxycytosine Nucleobase, J. Org. Chem., 2023, 88, 154−162

• GuNA™

  Shrestha AR, Kotobuki Y, Hari Y, Obika S.
  Guanidine Bridged Nucleic Acid (GuNA): an Effect of a Cationic Bridged Nucleic Acid on DNA Binding Affinity, Chem Commun 2014, 50, 5, 575-7

  Horie N, Kumagai S, Kotobuki Y, Yamaguchi T, Obika S.
  Facile Synthesis and Fundamental Properties of an N-methylguanidine-bridged Nucleic Acid (GuNA[NMe]), Org Biomol Chem. 2018,16, 35, 6531-6536.

  Kumagai S, Sawamoto H, Takegawa-Araki T, Arai Y, Yamakoshi S, Yamada K, Ohta Tetsuya, Kawanishi E, Horie N, Yamaguchi T, Obika S.
  Synthesis and Properties of GuNA purine/pyrimidine Nucleosides and Oligonucleotides, Org. Biomol. Chem., 2020, 18, 9461

  Horie N, Yamaguchi T, Kumagai S, Obika S.
  Synthesis and properties of oligonucleotides modified with an N-methylguanidine-bridged nucleic acid (GuNA[Me]) bearing adenine, guanine, or 5-methylcytosine nucleobases, Beilstein J. Org. Chem. 2021, 17, 622–629.

  Shimo T, Nakatsuji Y, Tachibana K, Obika S.
  Design and In Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids, Int. J. Mol. Sci. 2021, 22, 3526.

  Takegawa-Araki T, Kumagai S. Yasukawa K, Kuroda M, Sasaki T, Obika S.
  Structure−Activity Relationships of Anti-microRNA Oligonucleotides Containing Cationic Guanidine-Modified Nucleic Acids, J. Med. Chem. 2022, 65, 2139−2148

  Sasaki T, Hirakawa Y, Yamairi F, Kurita T, Murahashi K, Nishimura H, Iwazaki N, Yasuhara H, Tateoka T, Ohta T, Obika S, Kotera Jun.
  Altered Biodistribution and Hepatic Safety Profile of a Gapmer Antisense Oligonucleotide Bearing Guanidine-Bridged Nucleic Acids, Nucleic Acid Ther, 2022, 32, 3, 177-184

  Yamaguchi T, Horie N, Aoyama H, Kumagai S, Obika S.
  Mechanism of the Extremely High Duplex-forming Ability of Oligonucleotides Modified With N-tert-butylguanidine- or N-tert-butyl-N′-methylguanidine-bridged Nucleic Acids Nucleic acid research, 2023, 51, 7749

• 5′-CP™

  Kuroda T, Yoshioka K, Mon SSL, Katsuyama M, Sato K, Isogai E, Yoshida-Tanaka K, Iwata-Hara R, Yamaguchi T, Obika S, Yokota T.
  Unraveling and controlling late-onset neurotoxicity of antisense oligonucleotides through strategic chemical modifications, Molecular Therapy: Nucleic Acids , 2025, September 12, 102692